Parlux sales
This article was originally published in The Rose Sheet
Executive Summary
Net sales for the year increased 1.6% to $70 mil., Fort Lauderdale, Fla. fragrance distributor announces June 25. Net loss for the period was $5.7 mil., compared to net profit of $3.9 mil. the prior year period. Loss is attributed to $7.4 mil. non-cash charge related to the sale of two brands - Alexandra de Markoff and Bal de Versaille - and a $2.9 mil. non-cash charge "for an unrealized loss on an investment," firm says. Excluding the charges, the company earned $1.6 mil., Parlux says. Fourth quarter sales gained 12.5% to $16.7 mil., and net income in the period jumped 30% to $804,000. Parlux manufacturers Perry Ellis, Fred Hayman Beverly Hills, Ocean Pacific and Jockey fragrances...
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.